SUBSCRIBE
SUBSCRIBE
Ana Mulero

Ana Mulero

Freelance writer

Ana Mulero is a freelance writer based in Puerto Rico and Florida. She can be reached at anacmulero@outlook.com, on LinkedIn and on X @anitamulero.

A piggy bank crammed with $100 bills on a background of American cash
Business
Biotech Industry Overcomes Slump, Adapts to New Normal
M&A activity surges and IPOs return as the biotech industry navigates a changing business landscape marked by strategic consolidation and renewed investor focus on innovation.
August 14, 2024
 · 
6 min read
 · 
Ana Mulero
Pictured: A collage representing cell and gene the
Drug Development
5 Cell and Gene Therapy Decisions to Watch in 2024
From gene-corrected cell therapies to a new CAR-T, the cell and gene therapy space looks to expand its reach into the market.
April 17, 2024
 · 
9 min read
 · 
Ana Mulero
Pictured: Illustration of three faucets pouring co
Deals
Biotech Gets Creative to Avoid Bankruptcy in 2024
From the rising trend of royalty financing to other adaptive funding strategies, firms think outside the box in responding to unprecedented challenges.
January 8, 2024
 · 
4 min read
 · 
Ana Mulero
Money floats by skyscrapers, including one from wh
Deals
Biotech Bankruptcies Skyrocket
From Statera Biopharma and Sorrento Therapeutics to Aceragen and Infinity Pharmaceuticals, 2023 has seen a record high 28 bankruptcies in the biotech space so far. Here’s why.
October 10, 2023
 · 
6 min read
 · 
Ana Mulero
Pictured: Graphic of stock data overlaid over stac
Why Biopharma Companies Buy Stock in One Another
Biopharma companies buying stock in one another did not used to be an unusual practice, but experts told BioSpace this is becoming less common due to greater market volatility.
September 5, 2023
 · 
3 min read
 · 
Ana Mulero
Pictured: Abstract design of computer code/iStock,
Drug Development
Launch of Insilico’s Phase II Program Highlights Generative AI Momentum
Insilico’s AI platform has attracted interest from a growing number of biopharma companies. Meanwhile, several other firms highlight their own AI technologies.
August 11, 2023
 · 
5 min read
 · 
Ana Mulero
Pictured: An illustration of people, medicine, mon
Policy
IRA Creates Unintended Complications for Biologics
The new legislation could increase healthcare spending overall while reducing biopharma’s return on investment on biologic drugs.
August 8, 2023
 · 
4 min read
 · 
Ana Mulero
Pictured: An illustration of patients, doctors, me
Drug Development
FDA Launches Pilot Program to Develop Better Rare Disease Endpoints
The program—a joint initiative between CDER and CBER—aims to accelerate the development of therapies for rare diseases.
July 20, 2023
 · 
6 min read
 · 
Ana Mulero
Pictured: Group of pills/Courtesy, iStock, Sergii
Business
Humira Biosimilars and Others Face Uncertain Future Under IRA
Industry advocates argue price negotiation via the IRA may jeopardize the prices relied upon by biosimilar manufacturers to recoup their investments.
July 19, 2023
 · 
5 min read
 · 
Ana Mulero
Pictured: FDA Headquarters, iStock, Grandbrothers
Policy
FDA Centers Seek Regulatory Harmonization to Ease Industry Burden
The initiatives coincide with an increase in the volume of data submitted to CDER and CBER—particularly in cell and gene therapy.
June 29, 2023
 · 
5 min read
 · 
Ana Mulero
FDA sign outside its office in Maryland
Drug Development
FDA Braces for Looming Boom in Cell and Gene Therapy Submissions
The FDA has launched a new super office to prepare for myriad decisions on cell and gene therapies, including the potential first CRISPR therapy and the first gene therapy for Duchenne muscular dystrophy.
June 9, 2023
 · 
7 min read
 · 
Ana Mulero
Pictured: Graphic of DNA helix structure/iStock/an
FDA
Accelerated Approval of Gene Therapies Intensifies Reimbursement Questions
Efforts are underway to fast-track approval for costly gene therapies and make them affordable to a wider patient group via reimbursement through Medicare and Medicaid.
May 31, 2023
 · 
3 min read
 · 
Ana Mulero
Pictured: Technicolor warp speed. © Nicole Bean fo
FDA
CBER to Launch Operation Warp Speed for Rare Diseases by Year’s End
The FDA’s Center for Biologics Evaluation and Research is aiming to recreate the success achieved with the rapid development of COVID-19 vaccines under a program of the same name.
April 21, 2023
 · 
7 min read
 · 
Ana Mulero
Policy
Makena Saga Concludes as FDA Withdraws Approval for Only Preterm Birth Drug on Market
After 12 years on the market, the FDA announced it has withdrawn its previous approval for the only drug on the market to prevent preterm birth, Covis Pharma’s Makena.
April 7, 2023
 · 
3 min read
 · 
Ana Mulero
Pictured: Cancer patient in bed looking out window
Drug Development
Oncternal Therapeutics Cuts Two Programs Amidst Changing BTK Landscape
The money saved on canceling the existing studies is intended to fund the advancement of two other oncology pipeline assets.
April 4, 2023
 · 
2 min read
 · 
Ana Mulero
Load More